PDCD1 and hepatocellular carcinoma: Therefore, HAIC combined with PD-1 antibody and lenvatinib in the treatment of advanced HCC did not significantly increase serious adverse reactions, mainly manifested in chemotherapy-related adverse reactions and abdominal pain, which was relatively safe.